Ascendis Pharma A/S (FRA:A71)
Germany · Delayed Price · Currency is EUR 206.00
+2.00 (0.98%)
Inactive · Last trade price on Apr 17, 2026
Ascendis Pharma Financials Overview
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 720.13 | 720.13 | 363.64 | 266.72 | 51.17 | 7.78 |
Revenue Growth | 98.03% | 98.03% | 36.34% | 421.20% | 557.93% | 11.87% |
Gross Profit Gross Profit Growth | 625.22 | 625.22 | 319.38 | 222.32 | 39.04 | 4.26 |
Operating Income Operating Income Growth | -136.27 | -136.27 | -278.76 | -455.54 | -561.81 | -451.79 |
Net Income Net Income Growth | -228.03 | -228.03 | -378.08 | -481.45 | -583.19 | -383.58 |
Earnings Per Share EPS Growth | -3.76 | -3.76 | -6.53 | -8.55 | -10.40 | -7.00 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
YORVIPATH YORVIPATH Growth | 778.78 | 477.41 | 28.73 | - | - | - |
SKYTROFA SKYTROFA Growth | 203.29 | 206.16 | 197 | 178.66 | 35.66 | 0.94 |
Services and Clinical Supply Services and Clinical Supply Growth | 20.88 | 18.01 | 15.57 | 21.98 | 12.97 | 4.47 |
Licenses Licenses Growth | 6.53 | 5.63 | 122.34 | 66.08 | 2.55 | 2.37 |
Milestones Milestones Growth | - | 12.92 | - | - | - | - |
Revenue (Total) Revenue (Total) Growth | 1,047 | 720.13 | 363.64 | 266.72 | 51.17 | 7.78 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 616.04 | 616.04 | 559.54 | 399.44 | 742.95 | 789.63 |
Total Debt Total Debt Growth | 871.79 | 871.79 | 856.62 | 644.27 | 508.38 | 104.96 |
Net Cash (Debt) Net Cash Growth | -255.75 | -255.75 | -297.07 | -244.83 | 234.57 | 684.66 |
Net Cash Growth | - | - | - | - | -65.74% | -7.74% |
Net Cash Per Share Net Cash Per Share Growth | -4.22 | -4.22 | -5.13 | -4.35 | 4.18 | 12.50 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 53.9 | 53.9 | -306.2 | -467.36 | -495.7 | -417.65 |
Capital Expenditures CapEx Growth | -8.49 | -8.49 | -1.43 | -2.44 | -14.49 | -23.7 |
Free Cash Flow Free Cash Flow Growth | 45.41 | 45.41 | -307.62 | -469.8 | -510.19 | -441.35 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Gross Margin | 86.82% | 86.82% | 87.83% | 83.36% | 76.28% | 54.71% |
Operating Margin | -18.92% | -18.92% | -76.66% | -170.80% | -1097.85% | -5808.59% |
Pretax Margin | -29.53% | -29.53% | -102.64% | -177.77% | -1129.12% | -4936.28% |
Profit Margin | -31.67% | -31.67% | -103.97% | -180.51% | -1139.63% | -4931.56% |
FCF Margin | 6.31% | 6.31% | -84.60% | -176.14% | -996.97% | -5674.38% |